Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates.

Chimeric antigen receptor or CAR T-cell therapy is FDA approved to treat patients with blood cancers including non-Hodgkins lymphoma and acute lymphoblastic leukemia, whose disease persists or returns following first-line treatments. One reason CAR T-cell therapy is effective is because a patient’s blood contains an abundance of the cancer cells that stimulate the activation and expansion of the modified T-cells. 

The old adage that says two heads are better than one certainly seems true for Mitchell Ho, Ph.D., a senior investigator in the Center for Cancer Research (CCR), and Xiaolin Wu, Ph.D., a principal scientist in the Genomics Technology Laboratory, a CCR Core at the Frederick National Laboratory.